Skip to content

Effect of Yoga & Naturopathy in patients with COVID-19

NATUROPATHY AND YOGA IN THE MANAGEMENT OF COVID19 A Multi-center controlled clinical trial - YONAC Trial

Status
Recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/05/025320
Enrollment
658
Registered
2020-05-22
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Yoga & Naturopathy immune boostinng and stress management protocol: Essential: 1. Natural immune boosting fresh juice: Indian Gooseberry juice â?? 50ml Basil Juice â?? 50ml Ginger Juic

Sponsors

Government Yoga And Naturopathy Medical College Chennai
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: a) Written informed consent prior to performing study procedures. Witnessed oral consent will be accepted in order to avoid paper handling. Written consent by patient or their family members will be obtained wherever applicable. b) Male or Female adult patient >=18 years and c) Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR in naso/oropharyngeal swabs or any other relevant specimen d) Asymptomatic / uncomplicated illness / mild pneumonia COVID-19 as defined by ICMR

Exclusion criteria

Exclusion criteria: a) Explicit non-willingness to be a part of the research study b) Patients with moderate/severe stages of COVID19 c) Participation in any other clinical trials

Design outcomes

Primary

MeasureTime frame
Time to progress to next stage of severity i.e., from asymptomatic/uncomplicated/mild pneumonia to moderate/severe stagesTimepoint: At 15 days

Secondary

MeasureTime frame
Clinical endpoints 1. Time to All-cause mortality at discharge 2. All-cause mortality at 28 days Measures of morbidity 1. Number of days lived with infection 2. Number of days lived with intensive care if the disease has progressed to severe infection from asymptomatic, mild, and moderate stages. 3. Measuring the symptoms using standard scores Patient reported outcome 1. Quality of life as assessed by WHO-QoL BREF 2. Anxiety as assessed by GAD scale Safety outcomesTimepoint: At Discharge

Countries

India

Contacts

Public ContactManavalan Narayanaswamy

Government Yoga AND Naturopathy Medical College

gynmcchennai@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026